S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients
Background and Objectives This current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients. Methods This study included 100 stage III melanom...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2019-11, Vol.120 (6), p.1031-1037 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1037 |
|---|---|
| container_issue | 6 |
| container_start_page | 1031 |
| container_title | Journal of surgical oncology |
| container_volume | 120 |
| creator | Deckers, Eric A. Wevers, Kevin P. Muller Kobold, Anneke C. Damude, Samantha Vrielink, Otis M. Ginkel, Robert J. Been, Lukas B. Leeuwen, Barbara L. Hoekstra, Harald J. Kruijff, Schelto |
| description | Background and Objectives
This current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients.
Methods
This study included 100 stage III melanoma patients in follow‐up after curative lymph node dissection. Follow‐up visits included physical examination and S‐100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or elevated S‐100B.
Results
Of 100 patients, 13 (13%) had elevated S‐100B without clinical symptoms, of whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty‐six patients (26%) had clinical symptoms with normal S‐100B and FDG PET/CT revealed metastasis in 20 (77%). Three patients had clinical symptoms and elevated S‐100B, and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated S‐100B prompted early detection of asymptomatic disease; 10% of all asymptomatic patients in follow‐up, 23% of all patients with recurrent disease.
Conclusion
S‐100B cannot exclude recurrent disease during follow‐up of stage III melanoma. However, adding S‐100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma. |
| doi_str_mv | 10.1002/jso.25682 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6851671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2304775062</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4432-8892173d39413ececf3c0567e23a26918fdb7bbf02c012626b9e55c8c2d7247c3</originalsourceid><addsrcrecordid>eNp1kc1u1DAURi1ERYfCghdAltjAIh3_xY43SCW0ZapKReqwthyPM3jk2FM7oXTHI_CMPEldpq0AiZUX39HxvfcD4BVGhxghMt_keEhq3pAnYIaR5JVEsnkKZiUjFRMS7YPnOW8QQlJy9gzsU8x4U9N6BsLlrx8_i-QD1BnqAO33MWmYrbdmdDHAMUYP-5jgycdT-Pl4OW-XMBsdggtr6EKJvI_XxTFtYezh0VnbwjzqtYWLxQIO1usQBw23enQ2jPkF2Ou1z_bl_XsAvpwcL9tP1fnF6aI9Oq8MY5RUTSMJFnRFJcPUGmt6alDNhSVUEy5x06860XU9IgZhwgnvpK1r0xiyEoQJQw_A-513O3WDXZnyd9JebZMbdLpRUTv1dxLcV7WO31Q5C-YCF8Hbe0GKV5PNoxpcNtaXfWycsiKkoRhTRlhB3_yDbuKUQllPEYqYEDXipFDvdpRJMedk-8dhMFJ3LarSovrdYmFf_zn9I_lQWwHmO-DaeXvzf5M6u7zYKW8BOnGmRw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2304775062</pqid></control><display><type>article</type><title>S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Deckers, Eric A. ; Wevers, Kevin P. ; Muller Kobold, Anneke C. ; Damude, Samantha ; Vrielink, Otis M. ; Ginkel, Robert J. ; Been, Lukas B. ; Leeuwen, Barbara L. ; Hoekstra, Harald J. ; Kruijff, Schelto</creator><creatorcontrib>Deckers, Eric A. ; Wevers, Kevin P. ; Muller Kobold, Anneke C. ; Damude, Samantha ; Vrielink, Otis M. ; Ginkel, Robert J. ; Been, Lukas B. ; Leeuwen, Barbara L. ; Hoekstra, Harald J. ; Kruijff, Schelto</creatorcontrib><description>Background and Objectives
This current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients.
Methods
This study included 100 stage III melanoma patients in follow‐up after curative lymph node dissection. Follow‐up visits included physical examination and S‐100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or elevated S‐100B.
Results
Of 100 patients, 13 (13%) had elevated S‐100B without clinical symptoms, of whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty‐six patients (26%) had clinical symptoms with normal S‐100B and FDG PET/CT revealed metastasis in 20 (77%). Three patients had clinical symptoms and elevated S‐100B, and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated S‐100B prompted early detection of asymptomatic disease; 10% of all asymptomatic patients in follow‐up, 23% of all patients with recurrent disease.
Conclusion
S‐100B cannot exclude recurrent disease during follow‐up of stage III melanoma. However, adding S‐100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.25682</identifier><identifier>PMID: 31468535</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; biomarker ; Biomarkers, Tumor - metabolism ; Cancer surgery ; FDG PET/CT ; Female ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; follow‐up ; Humans ; Male ; Medical imaging ; Melanoma ; Melanoma - diagnostic imaging ; Melanoma - metabolism ; Melanoma - pathology ; Melanoma - surgery ; Metastasis ; Middle Aged ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - metabolism ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography - methods ; Radiopharmaceuticals ; recurrence ; S100 Calcium Binding Protein beta Subunit - metabolism ; S‐100B ; Tomography</subject><ispartof>Journal of surgical oncology, 2019-11, Vol.120 (6), p.1031-1037</ispartof><rights>2019 The Authors. Journal of Surgical Oncology published by Wiley Periodicals, Inc.</rights><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4432-8892173d39413ececf3c0567e23a26918fdb7bbf02c012626b9e55c8c2d7247c3</citedby><cites>FETCH-LOGICAL-c4432-8892173d39413ececf3c0567e23a26918fdb7bbf02c012626b9e55c8c2d7247c3</cites><orcidid>0000-0001-6206-207X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.25682$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.25682$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31468535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deckers, Eric A.</creatorcontrib><creatorcontrib>Wevers, Kevin P.</creatorcontrib><creatorcontrib>Muller Kobold, Anneke C.</creatorcontrib><creatorcontrib>Damude, Samantha</creatorcontrib><creatorcontrib>Vrielink, Otis M.</creatorcontrib><creatorcontrib>Ginkel, Robert J.</creatorcontrib><creatorcontrib>Been, Lukas B.</creatorcontrib><creatorcontrib>Leeuwen, Barbara L.</creatorcontrib><creatorcontrib>Hoekstra, Harald J.</creatorcontrib><creatorcontrib>Kruijff, Schelto</creatorcontrib><title>S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Background and Objectives
This current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients.
Methods
This study included 100 stage III melanoma patients in follow‐up after curative lymph node dissection. Follow‐up visits included physical examination and S‐100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or elevated S‐100B.
Results
Of 100 patients, 13 (13%) had elevated S‐100B without clinical symptoms, of whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty‐six patients (26%) had clinical symptoms with normal S‐100B and FDG PET/CT revealed metastasis in 20 (77%). Three patients had clinical symptoms and elevated S‐100B, and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated S‐100B prompted early detection of asymptomatic disease; 10% of all asymptomatic patients in follow‐up, 23% of all patients with recurrent disease.
Conclusion
S‐100B cannot exclude recurrent disease during follow‐up of stage III melanoma. However, adding S‐100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>biomarker</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer surgery</subject><subject>FDG PET/CT</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Follow-Up Studies</subject><subject>follow‐up</subject><subject>Humans</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Melanoma</subject><subject>Melanoma - diagnostic imaging</subject><subject>Melanoma - metabolism</subject><subject>Melanoma - pathology</subject><subject>Melanoma - surgery</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm Staging</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Radiopharmaceuticals</subject><subject>recurrence</subject><subject>S100 Calcium Binding Protein beta Subunit - metabolism</subject><subject>S‐100B</subject><subject>Tomography</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAURi1ERYfCghdAltjAIh3_xY43SCW0ZapKReqwthyPM3jk2FM7oXTHI_CMPEldpq0AiZUX39HxvfcD4BVGhxghMt_keEhq3pAnYIaR5JVEsnkKZiUjFRMS7YPnOW8QQlJy9gzsU8x4U9N6BsLlrx8_i-QD1BnqAO33MWmYrbdmdDHAMUYP-5jgycdT-Pl4OW-XMBsdggtr6EKJvI_XxTFtYezh0VnbwjzqtYWLxQIO1usQBw23enQ2jPkF2Ou1z_bl_XsAvpwcL9tP1fnF6aI9Oq8MY5RUTSMJFnRFJcPUGmt6alDNhSVUEy5x06860XU9IgZhwgnvpK1r0xiyEoQJQw_A-513O3WDXZnyd9JebZMbdLpRUTv1dxLcV7WO31Q5C-YCF8Hbe0GKV5PNoxpcNtaXfWycsiKkoRhTRlhB3_yDbuKUQllPEYqYEDXipFDvdpRJMedk-8dhMFJ3LarSovrdYmFf_zn9I_lQWwHmO-DaeXvzf5M6u7zYKW8BOnGmRw</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Deckers, Eric A.</creator><creator>Wevers, Kevin P.</creator><creator>Muller Kobold, Anneke C.</creator><creator>Damude, Samantha</creator><creator>Vrielink, Otis M.</creator><creator>Ginkel, Robert J.</creator><creator>Been, Lukas B.</creator><creator>Leeuwen, Barbara L.</creator><creator>Hoekstra, Harald J.</creator><creator>Kruijff, Schelto</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6206-207X</orcidid></search><sort><creationdate>20191101</creationdate><title>S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients</title><author>Deckers, Eric A. ; Wevers, Kevin P. ; Muller Kobold, Anneke C. ; Damude, Samantha ; Vrielink, Otis M. ; Ginkel, Robert J. ; Been, Lukas B. ; Leeuwen, Barbara L. ; Hoekstra, Harald J. ; Kruijff, Schelto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4432-8892173d39413ececf3c0567e23a26918fdb7bbf02c012626b9e55c8c2d7247c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>biomarker</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer surgery</topic><topic>FDG PET/CT</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Follow-Up Studies</topic><topic>follow‐up</topic><topic>Humans</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Melanoma</topic><topic>Melanoma - diagnostic imaging</topic><topic>Melanoma - metabolism</topic><topic>Melanoma - pathology</topic><topic>Melanoma - surgery</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm Staging</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Radiopharmaceuticals</topic><topic>recurrence</topic><topic>S100 Calcium Binding Protein beta Subunit - metabolism</topic><topic>S‐100B</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deckers, Eric A.</creatorcontrib><creatorcontrib>Wevers, Kevin P.</creatorcontrib><creatorcontrib>Muller Kobold, Anneke C.</creatorcontrib><creatorcontrib>Damude, Samantha</creatorcontrib><creatorcontrib>Vrielink, Otis M.</creatorcontrib><creatorcontrib>Ginkel, Robert J.</creatorcontrib><creatorcontrib>Been, Lukas B.</creatorcontrib><creatorcontrib>Leeuwen, Barbara L.</creatorcontrib><creatorcontrib>Hoekstra, Harald J.</creatorcontrib><creatorcontrib>Kruijff, Schelto</creatorcontrib><collection>Wiley Online Library</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deckers, Eric A.</au><au>Wevers, Kevin P.</au><au>Muller Kobold, Anneke C.</au><au>Damude, Samantha</au><au>Vrielink, Otis M.</au><au>Ginkel, Robert J.</au><au>Been, Lukas B.</au><au>Leeuwen, Barbara L.</au><au>Hoekstra, Harald J.</au><au>Kruijff, Schelto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>120</volume><issue>6</issue><spage>1031</spage><epage>1037</epage><pages>1031-1037</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background and Objectives
This current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients.
Methods
This study included 100 stage III melanoma patients in follow‐up after curative lymph node dissection. Follow‐up visits included physical examination and S‐100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or elevated S‐100B.
Results
Of 100 patients, 13 (13%) had elevated S‐100B without clinical symptoms, of whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty‐six patients (26%) had clinical symptoms with normal S‐100B and FDG PET/CT revealed metastasis in 20 (77%). Three patients had clinical symptoms and elevated S‐100B, and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated S‐100B prompted early detection of asymptomatic disease; 10% of all asymptomatic patients in follow‐up, 23% of all patients with recurrent disease.
Conclusion
S‐100B cannot exclude recurrent disease during follow‐up of stage III melanoma. However, adding S‐100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31468535</pmid><doi>10.1002/jso.25682</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-6206-207X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2019-11, Vol.120 (6), p.1031-1037 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6851671 |
| source | MEDLINE; Wiley Online Library Journals |
| subjects | Adult Aged Aged, 80 and over biomarker Biomarkers, Tumor - metabolism Cancer surgery FDG PET/CT Female Fluorodeoxyglucose F18 Follow-Up Studies follow‐up Humans Male Medical imaging Melanoma Melanoma - diagnostic imaging Melanoma - metabolism Melanoma - pathology Melanoma - surgery Metastasis Middle Aged Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - metabolism Neoplasm Staging Positron Emission Tomography Computed Tomography - methods Radiopharmaceuticals recurrence S100 Calcium Binding Protein beta Subunit - metabolism S‐100B Tomography |
| title | S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A06%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S%E2%80%90100B%20as%20an%20extra%20selection%20tool%20for%20FDG%20PET/CT%20scanning%20in%20follow%E2%80%90up%20of%20AJCC%20stage%20III%20melanoma%20patients&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Deckers,%20Eric%20A.&rft.date=2019-11-01&rft.volume=120&rft.issue=6&rft.spage=1031&rft.epage=1037&rft.pages=1031-1037&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.25682&rft_dat=%3Cproquest_pubme%3E2304775062%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2304775062&rft_id=info:pmid/31468535&rfr_iscdi=true |